Psoriasis and Heart Disease Risk: What the Inflammation Link Means for Your Cardiovascular Health

Psoriasis is classified as a systemic autoimmune disease, which means the immune malfunction behind your skin plaques is not confined to the surface. The same cytokines, particularly TNF-alpha, IL-17, and IL-23, that drive skin inflammation also accelerate atherosclerosis, the process by which arterial walls thicken and harden with fatty deposits. A 2013 study published in the Journal of the American Academy of Dermatology found that patients with severe psoriasis had a 58% higher risk of a major cardiovascular event compared to age-matched controls without the condition. Cardiologists now refer to this as the "psoriasis-cardiovascular axis", a recognised clinical relationship, not an incidental overlap.
The severity of your psoriasis matters here. Mild disease, covering less than 3% of body surface area, carries a modest elevation in cardiovascular risk. Moderate-to-severe psoriasis, the kind affecting the scalp, trunk, and joints, is associated with risk levels comparable to type 2 diabetes in terms of heart disease probability. Psoriatic arthritis, which develops in roughly 30% of psoriasis patients, adds another layer: joint inflammation correlates with even higher rates of endothelial dysfunction, the early-stage arterial damage that precedes a cardiac event.Psoriasis affects approximately 2 to 3% of the Indian population, with prevalence concentrated in northern states and among patients with a family history of autoimmune conditions. Indian dermatology data, including research from AIIMS New Delhi and the Indian Journal of Dermatology, points to a pattern worth noting: Indian psoriasis patients often present later, with more extensive skin involvement, partly because mild-to-moderate disease is frequently managed with topical treatments alone for years before systemic therapy is considered.
That delay matters for heart risk. Prolonged uncontrolled inflammation, even when the skin looks manageable, keeps inflammatory markers like C-reactive protein and homocysteine elevated over time. Indian patients also carry independent cardiovascular risk factors at higher baseline rates: South Asians have a genetic predisposition to visceral fat accumulation, insulin resistance, and dyslipidaemia. When psoriasis-driven inflammation layers onto those existing risks, the cardiovascular burden compounds rather than simply adds.A psoriasis diagnosis today, in any well-resourced dermatology clinic, should trigger a cardiovascular screening conversation. The minimum baseline includes blood pressure, fasting lipid profile, fasting glucose, and body mass index. For patients with moderate-to-severe disease or psoriatic arthritis, a high-sensitivity C-reactive protein test gives a direct read on systemic inflammation levels.
Biologics, the injectable therapies targeting specific cytokines, have changed the risk calculation. TNF-alpha inhibitors like adalimumab and etanercept, and IL-17 inhibitors like secukinumab, do not just clear skin. By suppressing the inflammatory cascade at its source, they reduce circulating inflammatory markers and have been associated in multiple cohort studies with lower rates of myocardial infarction in psoriasis patients on long-term treatment. A 2017 cohort study in JAMA Dermatology found that psoriasis patients on biologic therapy had a 20% lower risk of major cardiovascular events compared to those on conventional systemic treatments. This does not make biologics a heart medication, but it does mean that undertreating severe psoriasis carries a cardiac cost that goes beyond skin clearance scores.Smoking doubles the cardiovascular risk in psoriasis patients beyond what either condition contributes alone. Alcohol, a common psoriasis trigger in Indian men, raises triglycerides and worsens inflammation simultaneously. Obesity is both a risk factor for psoriasis onset and a driver of its severity, visceral fat tissue itself produces inflammatory cytokines that feed the same pathways the disease uses.

Diet has a direct role. A 2018 study in JAMA Dermatology found that caloric restriction and weight loss in obese psoriasis patients produced meaningful reductions in psoriasis area severity scores, independent of any medication change. Anti-inflammatory dietary patterns, emphasising omega-3 fatty acids, vegetables, and limiting processed carbohydrates, have a plausible mechanism in psoriasis management, though they are not a substitute for systemic treatment in moderate-to-severe disease.
Regular aerobic exercise reduces both systemic inflammation and cardiovascular risk. Thirty minutes of moderate-intensity activity on most days lowers C-reactive protein levels measurably over twelve weeks. For psoriasis patients with active joint disease, low-impact options, swimming, cycling, walking, carry the same anti-inflammatory benefit without aggravating inflamed joints.If you have had a psoriasis diagnosis for more than five years, or if your disease is classified as moderate-to-severe, ask your dermatologist directly about cardiovascular screening. Request a lipid panel if you have not had one recently. If you are on a biologic, your rheumatologist or dermatologist should already be monitoring metabolic markers, confirm that this is part of your follow-up protocol.

Psoriatic arthritis patients in particular should be under the care of both a rheumatologist and a dermatologist, with a cardiologist involved if any metabolic risk factors are present. The skin is where psoriasis is visible. The arteries are where its long-term consequences accumulate silently.
The disease you can see on the surface and the risk building inside the arterial wall are not two separate problems requiring two separate doctors. The inflammation is the same inflammation, running through the same bloodstream, toward the same organ. Managing psoriasis aggressively is, in a precise and measurable sense, also managing heart disease risk.